about
Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicinePaucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.Cost-effectiveness of a telephone-delivered intervention for physical activity and dietCost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.Budget impact analysis of switching to digital mammography in a population-based breast cancer screening program: a discrete event simulation model.Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.The use of economic evaluation in CAM: an introductory framework.Cost effectiveness analysis in health care: contraindications."Budget impact analyses": a practical policy making tool for drug reimbursement decisionsThe business case for preconception care: methods and issues.Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers.The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program.Budget impact from the incorporation of positron emission tomography - computed tomography for staging lung cancers.Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyImpact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.Early retirement and the influence on healthcare budgets and insurance premiums in a diabetes population.Clinical Practice Variation Needs to be Considered in Cost-Effectiveness Analyses: A Case Study of Patients with a Recent Transient Ischemic Attack or Minor Ischemic Stroke.Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in SpainCost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.Finding legitimacy for the role of budget impact in drug reimbursement decisions.Effects of introducing a clinical guideline on the cost of treating dyspeptic syndrome.The use of modeling in the economic evaluation of vaccines.General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals.A critical systematic review of budget impact analyses on drugs in the EU countries.Health economics and outcomes methods in risk-based decision-making for blood safety.Budget impact analysis of medicines: updated systematic review and implications.A Methodological Review of US Budget-Impact Models for New Drugs.What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges.Clinical and economic effects of central venous catheters on oncology patient care.Calculation of prevalence with Markov models: budget impact analysis of thrombolysis for stroke.The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.
P2860
Q28756810-AC2FB680-1AF4-4D0C-93DA-55DFB21AFAA6Q30387509-6B047A33-48EA-4B1D-A645-72A432ED30BBQ33506631-6468E92E-AC6E-409A-8598-C16D2EC22C29Q33510685-EF80D2E6-3DC7-4AB8-8E62-6DADDD289AE1Q33617993-528E3F42-A9E9-4A2B-A4F1-97999D2FF815Q33701842-BAF5C9BA-EECB-4E54-970C-133809309183Q33743692-0FAC8E59-D95A-495F-93B8-EA8C8262E606Q33812436-7E6D1531-4CB0-44A0-A4B5-2ED4601D498BQ34256272-465EAA5F-619A-4AB1-8277-BA80E69CD6B8Q35069382-FE87B382-A358-4E0B-89D2-C2315B2D3170Q35616132-6DF56848-4460-4606-93DD-DA2EF5122E7BQ35887754-BA66B4BB-A82C-4D7C-A086-B209F60C8A30Q35981268-52948706-4F73-4088-82C0-E29F7C5431BCQ36110773-9A37FD07-0DB3-47C5-B606-B25CDB4568CEQ36171531-90C279B7-6E9D-4398-BE2A-7B4181EEED18Q36409734-862EC99E-6EF8-48AF-8095-91697752C406Q36541452-BEA03104-C3F7-4F83-9B1C-E64B9B1B413AQ36541703-42A7A572-9C0A-4E1C-9950-0935801EF8E4Q36836603-1DA85AA5-1A46-4068-85BF-E79AB21B921DQ36944056-70C16E31-328B-4ABA-8027-EAA2A6D6348AQ37081034-1F20C7D3-7C3B-4456-8738-1D312B55159AQ37363378-AE2E9610-5DE3-4B1E-9E7A-9B8ABB110E8DQ37609197-FD46FE16-7CFD-4AB7-8AF1-CC8E092E8A0BQ37609296-25365000-4A64-4DA8-AFC5-C5CC4293698FQ37780536-DD864230-BBBA-4018-9CA4-E27E8F088AF6Q38155481-4B49F208-50DB-4AFF-A5BD-72257BBD038BQ38412277-B636C485-090D-4C9D-A1C2-FE6397E23E41Q38753699-1AB7A53B-15F6-4097-B55C-203B241DA232Q38873634-BA22281B-A72D-4832-A2EC-3F1541CDC206Q38921107-00499CA3-17BB-4E07-A437-986F02AA6F5CQ38994340-767CF660-6F1D-4A06-9494-F74B629013EAQ39403982-75A6999C-2376-4BA7-A934-8D778FE6F513Q40041895-2DE295B0-C691-4284-BAEF-A20E0A82A1F3Q47299182-B23AB9D0-E429-4E7F-9610-081CF5B54FC2Q47908189-391FCC9E-DE2E-4736-8EE8-232F535CF421Q48375195-3F52FCFE-4243-4EA9-B239-00DF34B9E69AQ50070026-1E2909C1-205C-4BD9-B4E6-6665624237D4Q50969592-C72CBC8D-8206-4111-A00A-6B84483F15DAQ51114922-AAFEF696-C3CF-4AAD-BEBB-BD34F8C27493Q53860668-306FFFC5-FAEE-4B3B-A3D5-77A1DCD68B39
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Developing guidance for budget impact analysis.
@ast
Developing guidance for budget impact analysis.
@en
Developing guidance for budget impact analysis.
@nl
type
label
Developing guidance for budget impact analysis.
@ast
Developing guidance for budget impact analysis.
@en
Developing guidance for budget impact analysis.
@nl
prefLabel
Developing guidance for budget impact analysis.
@ast
Developing guidance for budget impact analysis.
@en
Developing guidance for budget impact analysis.
@nl
P2093
P1433
P1476
Developing guidance for budget impact analysis.
@en
P2093
P304
P356
10.2165/00019053-200119060-00001
P577
2001-01-01T00:00:00Z
P5875
P6179
1039225124